Pulmonary Hypertension Clinical Trial
— NOCaPHOfficial title:
Role of the Nitric Oxide (NO) in Pre-oxygenation Before Anesthetic Induction in Patients With a Pulmonary Hypertension in Cardiac Surgery. Pilot Study of Feasibility
The pulmonary hypertension (HTP) due to a left heart disease or a hypoxemiant lung disease is
frequent in cardiac surgery. The HTP represents an independent risk factor of morbidity and
mortality in cardiac surgery, entering to the criteria of Euroscore evaluation (European
System for Cardiac Operative Risk Evaluation).
An acute perioperative hemodynamic decompensation of these patients is frequent.
Perioperative hemodynamic modifications, hypoxemia, hypercapnia, sympathetic stimulation,
increase pulmonary vascular resistances (RVP) and might provoke right ventricular failure.
The anesthetic induction and the beginning of mechanical ventilation are the most sensible
times due to the risk of hemodynamic decompensation. The suppression of the sympathetic tonus
which is consequence of the anesthetic induction, decrease the systemic vascular resistances
and lead to decrease of blood pressure. In return, the anesthetic induction is associated
with an increase of pulmonary vascular resistances, resulting in increase of the postcharge
and the work of the right ventricle (VD). These systemic and pulmonary hemodynamic
modifications can lead to equalization, or even an inversion of the systemic and pulmonary
pressures. As consequence, a hemodynamic collapse or even a heart arrest can arise.
The patients suffering from HTP are hypoxemic. They have very limited oxygen reserves due to
decrease of the functional residual capacity (CRF). The apnea period, which follows the
anesthetic induction, is often associated with a fast desaturation, even if a good
pre-oxygenation was performed before. This desaturation causes an increase of the pulmonary
vascular resistances with the hemodynamic consequences previously mentioned. A risk of
hypoxic heart arrest is also present.
Nitric Oxide (NO) is an endogenous mediator produced from the vascular endothelium. The NO is
a powerful vasodilator and is used in intensive care in inhaled way as selective pulmonary
vasodilator (iNO). NO decreases the RVP, the shunt effect and improves the oxygenation by
optimization of ventilation-perfusion ratio. The short lifetime of iNO (6sec approximately)
allows a fast metabolism without inducing any undesirable effects such as the systemic
hypotension.
No studies, until now, have investigated the use of iNO in pre-oxygenation before anesthetic
induction in cardiac surgery.
We hope to demonstrate that iNO used in oxygenation before anesthetic induction will have a
beneficial effect on the respiratory and cardiovascular parameters.
Our objective is to estimate the feasibility and the tolerance of iNO before anesthetic
induction of the patients with a moderate or severe HTP programmed for cardiac surgery with
extracorporeal circulation. The effect will be estimated in terms of efficiency (hemodynamic
and respiratory optimization).
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 2019 |
Est. primary completion date | December 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age > 18 years old - Open-heart cardiac surgery - HTP Pulmonary hypertension (class 2 or 3) with PAPs (Systolic pulmonary artery pressure) > 40 mmHg diagnosed by preoperative righ cardiac catheterization or by transthoracic echocardiography. - Patient have signed their consent according to the modalities described by the Code of Public health system. - Patients affiliated to a national insurance (social security) system. Exclusion Criteria: - Heart transplant - HTP of type 1, 4, 5 according to the classification of Dana Point(2008) - Deficit in methemoglobin reductase - Protocole refuse from patient |
Country | Name | City | State |
---|---|---|---|
France | CHU de Clermont-Ferrand | Clermont-Ferrand |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Clermont-Ferrand | ARAMU Association |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pulmonary arterial systolic, diastolic and mean pressure | These measures will be taken each minute between t0 (conditioning of the patient's arrival in the operating room) and the time when FiO2 (Fraction of inspired oxygen) will be 60% (when the endotracheal tube is in place, between 30 and 40 minutes after t0) | at day 1 | |
Primary | Pulmonary arterial mean/arterial mean ratio | These measures will be taken each minute between t0 (conditioning of the patient's arrival in the operating room) and the time when FiO2 (Fraction of inspired oxygen) will be 60% (when the endotracheal tube is in place, between 30 and 40 minutes after t0) | at day 1 | |
Primary | SpO2 (Pulsed oxygen saturation) | These measures will be taken each minute between t0 (conditioning of the patient's arrival in the operating room) and the time when FiO2 (Fraction of inspired oxygen) will be 60% (when the endotracheal tube is in place, between 30 and 40 minutes after t0) | at day 1 | |
Primary | FeO2 (Fraction expired oxygen) (data not available just during intubation phase) | These measures will be taken each minute between t0 (conditioning of the patient's arrival in the operating room) and the time when FiO2 (Fraction of inspired oxygen) will be 60% (when the endotracheal tube is in place, between 30 and 40 minutes after t0) | at day 1 | |
Primary | Cardiac index | These measures will be taken each minute between t0 (conditioning of the patient's arrival in the operating room) and the time when FiO2 (Fraction of inspired oxygen) will be 60% (when the endotracheal tube is in place, between 30 and 40 minutes after t0) | at day 1 | |
Primary | Systemic vascular resistances | These measures will be taken each minute between t0 (conditioning of the patient's arrival in the operating room) and the time when FiO2 (Fraction of inspired oxygen) will be 60% (when the endotracheal tube is in place, between 30 and 40 minutes after t0) | at day 1 | |
Primary | SVO2 (Central Venous Saturation) | These measures will be taken each minute between t0 (conditioning of the patient's arrival in the operating room) and the time when FiO2 (Fraction of inspired oxygen) will be 60% (when the endotracheal tube is in place, between 30 and 40 minutes after t0) | at day 1 | |
Primary | Sat O2 (Blood oxygen saturation) | These measures will be taken each minute between t0 (conditioning of the patient's arrival in the operating room) and the time when FiO2 (Fraction of inspired oxygen) will be 60% (when the endotracheal tube is in place, between 30 and 40 minutes after t0) | at day 1 | |
Primary | PaO2 (Partial pressure of arterial oxygen) | These measures will be taken each minute between t0 (conditioning of the patient's arrival in the operating room) and the time when FiO2 (Fraction of inspired oxygen) will be 60% (when the endotracheal tube is in place, between 30 and 40 minutes after t0) | at day 1 | |
Primary | MetHb (methemoglobin) | These measures will be taken each minute between t0 (conditioning of the patient's arrival in the operating room) and the time when FiO2 (Fraction of inspired oxygen) will be 60% (when the endotracheal tube is in place, between 30 and 40 minutes after t0) | at day 1 | |
Secondary | Systolic, diastolic and mean arterial pressure | These measures will be taken each minute between t0 (conditioning of the patient's arrival in the operating room) and the time when FiO2 will be 60% (when the endotracheal tube is in place, between 30 and 40 minutes after t0) | at day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01950585 -
Hydroxyurea in Pulmonary Arterial Hypertension
|
Early Phase 1 | |
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Completed |
NCT03649932 -
Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
|
Phase 1 | |
Recruiting |
NCT04554160 -
Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
|
||
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT01894035 -
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
|
||
Not yet recruiting |
NCT04083729 -
Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy
|
N/A | |
Terminated |
NCT02243111 -
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound
|
N/A | |
Terminated |
NCT02246348 -
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
|
N/A | |
Completed |
NCT02216279 -
Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension
|
Phase 2 | |
Completed |
NCT02821156 -
Study on the Use of Inhaled NO (iNO)
|
N/A | |
Recruiting |
NCT01913847 -
Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT06240871 -
Contrast Enhanced PA Pressure Measurements
|
||
Completed |
NCT02377934 -
Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
|
||
Recruiting |
NCT01091012 -
Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT01463514 -
Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension
|
N/A | |
Completed |
NCT02275793 -
The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
|
||
Completed |
NCT01484899 -
Smoking: a Risk Factor for Pulmonary Arterial Hypertension?
|
N/A | |
Completed |
NCT00739375 -
The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension.
|
Phase 1 |